Achievements and unmet needs in the management of advanced ovarian cancer
- 1 May 2010
- journal article
- review article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 117 (2), 152-158
- https://doi.org/10.1016/j.ygyno.2009.11.033
Abstract
No abstract availableThis publication has 95 references indexed in Scilit:
- Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experienceCancer, 2010
- Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trialGynecologic Oncology, 2009
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroupJournal of Clinical Oncology, 2009
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Estimates of the cancer incidence and mortality in Europe in 2006Annals Of Oncology, 2007
- Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete RemissionJournal of Clinical Oncology, 2006
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Intraperitoneal cisplatin‐based chemotherapy vs. intravenous cisplatin‐based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancerInternational Journal of Gynecology & Obstetrics, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996